一、负责和参与的项目 1、国家自然科学基金面上项目，81772521，LMAR/SREBP1a调控肝内胆管癌脂代谢重编程的机制研究，2018.01-2021.12,52万，结题，主持 2、上海交通大学医学院多中心临床研究项目，DLY201807,基于专病数据库的胆道恶性肿瘤手术优化及预后判断辅助系统的多中心临床研究，2019.01-2021.12,50万，结题，主持 3、上海交通大学医学院附属新华医院院级临床研究培育基金项目，17CSK06，基于贝叶斯网络及重要度理论的胆囊癌手术优化选择及预后精确判断的多个中心临床研究，2017.10-2020.10,30万，结题，主持 4、上海新华医院千天项目，自体脐血回输在新生儿疾病规范治疗中的可行性研究，2016.01-2018.12，10万，结题，主持 5、上海市第四轮公共卫生重点学科建设项目-输血医学（上海市卫计委，15GWZK0501），2016.01-2017.12,15万，结题，参与 二、学术成果及重要论文 1、Xiaopeng Yu, Huanjun Tong, Jialu Chen, et al. CircRNA MBOAT2 promotes intrahepatic cholangiocarcinoma progression and lipid metabolism reprogramming by stabilizing PTBP1 to facilitate FASN mRNA cytoplasmic export. Cell Death &Disease. 2023,14(1):20. 2、Li Q, Zhang J, Chen C, Song T, Qiu Y, Mao X, Wu H, He Y, Cheng Z, Zhai W, Li J, Zhang D, Geng Z and Tang Z (2022) A Nomogram Model to Predict Early Recurrence of Patients With Intrahepatic Cholangiocarcinoma for Adjuvant Chemotherapy Guidance: A Multi-Institutional Analysis. Front. Oncol. 12:896764. 3、Qi Li，Chen Chen，Jingbo Su，and et al. Recurrence and prognosis in intrahepatic cholangiocarcinoma patients with different etiology after radical resection: a multi-institutional study. BMC Cancer. 2022,22:329. 4、Chen J, Yu X, Tong H, Tang C and Tang Z (2022) Establishment and experimental validation of a novel cuproptosis-related gene signature for prognostic implication in cholangiocarcinoma. Front. Oncol. 12:1054063. 5、Yongfu Xiong，Li Jingdong，Tang Zhaohui，and et al. A Consensus Meeting on Expert Recommendations on Operating Specifications for Laparoscopic Radical Resection of Hilar Cholangiocarcinoma. Front Surg. 2021,23(8):731448. 6、Qi Li, Chen Chen, Jian Zhang, and et al. Prediction Efficacy of Prognostic Nutritional Index and Albumin Bilirubin Grade in Patients With Intrahepatic Cholangiocarcinoma After Radical Resection: A Multi-Institutional Analysis of 535 Patients. Frontiers in Oncology. 2021,11:769696. 7、Chen Chen,Zhang Rui,Wu Yuhan,and et al. Optimal lymph Node Staging System in Evaluating Prognosis of Gallbladder Carcinoma:A multi-institutional Study. Ann Surg Oncol. 2021,28(13):8142-8151. 8、Shouhua Wang, Huanjun Tong, Tingting Su, and et al. CircTP63 promotes cell proliferation and invasion by regulating EZH2 via sponging miR‑217 in gallbladder cancer. Cancer Cell international, 2021,21(1):608. 9、侯忱, 龚繁, 刘红波, et al. 患者血液管理在复杂成人心胸外科手术应用分析. 中国输血杂志, 2021, 34(02): 139-42. 10、中华医学会临床输血学分会，中国医师协会输血科医师分会. 中国临床输血未来10年学科建设发展专家共识. 中国输血杂志, 2021,34(10): 1061-1065. 11、北京医学会输血医学分会，北京医师协会输血专业专家委员会. 中国输血医师规范化培训实施方案专家共识. 临床输血与检验. 2021,23（1）：1-5. 12、LI J, XIONG Y, YANG G, et al. Complete laparoscopic radical resection of hilar cholangiocarcinoma: technical aspects and long-term results from a single center . Wideochir Inne Tech Maloinwazyjne, 2020, 16(1): 62-75. 13、Jingdong L, Yongfu X, Yang G, et al. Minimally invasive surgery for hilar cholangiocarcinoma: a multicenter retrospective analysis of 158 patients. Surgical Endoscopy. 2020. 14、Yuhan Wu，Qi Li, Zhaohui Tang and et al. Survival prediction for gallbladder carcinoma after curative resection: Comparison of nomogram and Bayesian network models. European Journal of Surgical Oncology, 2020,46(11):2106-2113. 15、Yang F, Tang Z, Duan A and et al. Long Noncoding RNA NEAT1 Upregulates Survivin and Facilitates Gallblandder Cancer Progression by Sponging microRNA-335.OncoTargets and Therapy.2020:13 2356-2367. 三、专利 1、一种单孔腹腔镜专用穿刺器，第一发明人 2、腹腔镜肝切除治疗肝内胆管癌的远期预后的动态列线图模型构建方法、系统及应用，第三发明人